文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

利用淋球菌基因组公共数据库检测与唑利氟达星耐药相关突变

Using a public database of Neisseria gonorrhoeae genomes to detect mutations associated with zoliflodacin resistance.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究利用PathogenWatch公共数据库纳入12 493株淋病奈瑟菌基因组,通过BLAST搜索与唑利氟达星MIC升高相关的GyrB三个氨基酸突变(D429N、K450N、K450T),未发现任何基因组携带这些突变;仅1株在GyrB第429位存在D429V突变,提示相关耐药突变流行率极低。

要点

  • 在12 493株淋球菌基因组中未检出与唑利氟达星MIC升高相关的GyrB D429N、K450N或K450T突变。
  • 仅1株基因组在GyrB第429位存在D429V突变,其与唑利氟达星耐药的关系未明确。
  • PathogenWatch等基因组流行病学平台可用于增强淋球菌抗菌药物耐药性的全球监测。

核心结论

  • 与唑利氟达星耐药相关的三个GyrB氨基酸突变在淋球菌中的流行率非常低。
  • 仍需进一步研究淋球菌对唑利氟达星的耐药机制。

研究设计与样本

  • 基于PathogenWatch公共数据库纳入12 493株淋病奈瑟菌基因组,提取gyrB序列并用BLAST搜索目标突变。
  • 以GyrA S91F突变检出作为搜索方法学对照,并与PathogenWatch数据库比较。

主要发现

  • 12 493株基因组中无任何菌株携带GyrB D429N、K450N或K450T突变。
  • 1株基因组在GyrB第429位存在D429V突变。

关键数值与推荐

  • 目标突变为与唑利氟达星MIC升高相关的GyrB D429N、K450N和K450T。
  • 共纳入12 493株淋病奈瑟菌基因组进行分析。

临床怎么用

  • 提示当前淋球菌中唑利氟达星相关耐药突变的流行率极低,但需持续基因组监测。
  • 基因组流行病学平台可用于淋球菌抗菌药物耐药性的全球监测。

局限性

  • 结果基于公共数据库基因组,可能受采样与地理代表性限制。
  • 仅检测三个已知GyrB突变,未全面评估唑利氟达星耐药机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is an urgent global health threat. Zoliflodacin is a novel antibiotic undergoing clinical trials for the treatment of gonorrhoea. While there are limited data regarding zoliflodacin resistance in N. gonorrhoeae, three amino acid mutations have been associated with increased MICs of zoliflodacin. OBJECTIVES: To determine the prevalence of three amino acid mutations associated with zoliflodacin resistance within a large, public database of nearly 13 000 N. gonorrhoeae genomes. METHODS: PathogenWatch is an online genomic epidemiology platform with a public database of N. gonorrhoeae genomes. That database was used to extract gyrB sequence data and a Basic Local Alignment Search Tool (BLAST) search was performed to identify any of the three amino acid mutations in GyrB that are associated with increased zoliflodacin MICs: D429N, K450N or K450T. As a control for the search methodology, all GyrA sequences were also extracted and S91F mutations were identified and compared with the PathogenWatch database. RESULTS: In total, 12 493 N. gonorrhoeae genomes from the PathogenWatch database were included. Among those genomes, none was identified that harboured any of the three mutations associated with increased zoliflodacin MICs. One genome was identified to have a mutation at position 429 in GyrB (D429V). CONCLUSIONS: The findings suggest that the prevalence of the three mutations associated with zoliflodacin resistance in N. gonorrhoeae is very low. However, further research into the mechanisms of zoliflodacin resistance in N. gonorrhoeae is needed. Genomic epidemiology platforms like PathogenWatch can be used to enhance the global surveillance of AMR.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Adamson PC, Lin EY, Ha SM, et al. Using a public database of Neisseria gonorrhoeae genomes to detect mutations associated with zoliflodacin resistance. J Antimicrob Chemother. 2021. PMID: 34324655. doi:10.1093/jac/dkab262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。